Paul Hastings Continues HK Biotech IPO Spree with SinoMab BioScience’s Debut

November 12, 2019

Hong Kong and Shanghai – Paul Hastings, a leading global law firm, announced today that it has advised SinoMab BioScience Limited in its US$176.5 million global offering and IPO on the Main Board of the Hong Kong Stock Exchange (“HKSE”). SinoMab BioScience is a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, primarily in monoclonal antibody-based biologics. China International Capital Corporation Hong Kong Securities Limited and Orient Capital (Hong Kong) Limited acted as the joint sponsors, joint global coordinators, joint bookrunners and joint lead managers for the global offering.

SinoMab BioScience listed on the HKSE under Chapter 18A of the Hong Kong listing rules. Paul Hastings has recently advised some of the most representative biotech and healthcare companies on their listings in Hong Kong, including Ascletis Pharma, the first listing under Chapter 18A; Jinxin Fertility Group, the first assisted reproductive services company listed on the HKSE; and CanSino Biologics, the first vaccine company listed on the HKSE.
The Paul Hastings team was led by our corporate partners and the co-head of the firm’s mainland China offices Jia Yan and David Wang, with support from Hong Kong corporate partners Samuel Ng and Jason Kuo, Beijing associates Ting Wang and Yimin Tang, and Shanghai China associate Devin Geng.

At Paul Hastings, our purpose is clear — to help our clients and people navigate new paths to growth. With a strong presence throughout Asia, Europe, Latin America, and the U.S., Paul Hastings is recognized as one of the world’s most innovative global law firms.